search
Back to results

Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children

Primary Purpose

Amblyopia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Eye patch
Spectacles
Sponsored by
Jaeb Center for Health Research
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Amblyopia

Eligibility Criteria

3 Years - 7 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 3 to <7 years Able to perform visual acuity using the ATS single-surround HOTV protocol Amblyopia associated with strabismus (comitant or incomitant), anisometropia, or both Visual acuity in the amblyopic eye 20/40 to 20/400 inclusive Visual acuity in the sound eye >20/40 Inter-eye acuity difference >3 logMAR lines Cycloplegic refraction and ocular examination within 2 months prior to enrollment Exclusion Criteria: No amblyopia treatment (other than spectacles) in the past month and no more than one month of amblyopia treatment in the past 6 months No current vision therapy or orthoptics No ocular cause for reduced visual acuity No myopia more than a spherical equivalent of -6.00 D No prior intraocular or refractive surgery No known skin reactions to patch or bandage adhesives

Sites / Locations

  • Southern California College of Optometry
  • Duke University Eye Center

Outcomes

Primary Outcome Measures

maximal improvement in visual acuity

Secondary Outcome Measures

Full Information

First Posted
September 20, 2004
Last Updated
March 23, 2010
Sponsor
Jaeb Center for Health Research
Collaborators
National Eye Institute (NEI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00091923
Brief Title
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
Official Title
A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old
Study Type
Interventional

2. Study Status

Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Jaeb Center for Health Research
Collaborators
National Eye Institute (NEI)

4. Oversight

5. Study Description

Brief Summary
The objectives of the Spectacle Phase are: In previously untreated pure anisometropic patients (i.e. patients who have not used spectacles in the last year and who do not have strabismus), to determine the incidence of resolution of amblyopia with spectacle correction alone and the time course of visual acuity improvement with spectacle correction alone. In all other patients, to achieve maximal improvement with spectacle correction prior to entering the randomized trial. The objectives of the Randomized Trial are: To determine whether 5 weeks of patching treatment (2 hours of patching per day of the sound eye combined with at least one concurrent hour of near activities), compared with a control group (using spectacle correction only), improves visual acuity in patients with moderate to severe amblyopia (20/40 to 20/400). To determine the maximal improvement and time course of improvement with this patching treatment regimen.
Detailed Description
There are few data on the improvement that occurs with spectacle correction alone in cases of anisometropic amblyopia. The only published study of which we are aware is that of Moseley, et al, who found that 8 of 12 patients prescribed spectacles for the first time improved 3 or more lines in the amblyopic eye. Therefore, the Spectacle Phase of the current study will provide important information related to the management of patients with anisometropic amblyopia. Additionally, despite clinical experience that strongly indicates that amblyopia can be improved with treatment, there are those who claim that the benefit of treatment is unproven. Although improvement with amblyopia therapy has been shown in prospective trials, there have been no conclusive data published from a randomized trial evaluating the effect of amblyopia treatment compared with a control group. Therefore, we have designed a randomized trial to definitively address this issue. In the trial, the effect on amblyopic eye acuity after five weeks of 2 hours of prescribed daily patching (combined with at least one hour of concurrent near activities) will be compared with a control group using spectacle correction only. In a study conducted by the Pediatric Eye Disease Investigator Group, a 2-hour daily patching treatment regimen improved moderate amblyopia (20/40 to 20/80) by an amount similar to the improvement seen with 6 hours of daily patching. At the end of five weeks, patients whose amblyopic eye has improved from baseline will continue in follow up, using the assigned treatment, until the amblyopic eye acuity stops improving or until the amblyopia resolves. This will provide data on the maximum improvement achievable with this treatment regimen and on the time course to reach maximal improvement. There is no known harm in deferring treatment of amblyopia for five weeks in the age range to be included in the trial (3 to <7 years old). Standard care for a patient with amblyopia includes prescribing spectacle correction and having the patient return in 4 to 6 weeks for measurement of visual acuity. Spectacles alone are continued as long as the acuity in the amblyopic eye is improving. Once the acuity stops improving, occlusion or other active treatment is initiated. The maximum delay in active treatment of the control group beyond the standard of care is 5 weeks. In our prior Amblyopia Treatment Study protocols on patients in this age range, we have found no indication that the response to patching treatment is related to age. Therefore, it is highly unlikely that a delay in initiating treatment of weeks or even months could be harmful. This study is addressing issues related to the treatment of amblyopia in children 3 to <7 years old with visual acuity 20/40 to 20/400. The study consists of two phases: a Spectacle Phase in which patients are prescribed spectacles and followed until maximal improvement in visual acuity has occurred and a Randomized Trial comparing a group using patching treatment (in addition to spectacle correction) with a control group using spectacle correction only. The sample size for the primary analysis for the randomized trial has been estimated to be 134 patients. Patients will be enrolled into the Spectacle Phase until the recruitment goal for the Randomized Trial is reached.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amblyopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
268 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Eye patch
Intervention Type
Device
Intervention Name(s)
Spectacles
Primary Outcome Measure Information:
Title
maximal improvement in visual acuity

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 3 to <7 years Able to perform visual acuity using the ATS single-surround HOTV protocol Amblyopia associated with strabismus (comitant or incomitant), anisometropia, or both Visual acuity in the amblyopic eye 20/40 to 20/400 inclusive Visual acuity in the sound eye >20/40 Inter-eye acuity difference >3 logMAR lines Cycloplegic refraction and ocular examination within 2 months prior to enrollment Exclusion Criteria: No amblyopia treatment (other than spectacles) in the past month and no more than one month of amblyopia treatment in the past 6 months No current vision therapy or orthoptics No ocular cause for reduced visual acuity No myopia more than a spherical equivalent of -6.00 D No prior intraocular or refractive surgery No known skin reactions to patch or bandage adhesives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David K. Wallace, M.D.
Organizational Affiliation
Duke University Eye Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Susan A. Cotter, O.D.
Organizational Affiliation
Southern California College of Optometry at Marshall B. Ketchum University
Official's Role
Study Chair
Facility Information:
Facility Name
Southern California College of Optometry
City
Fullerton
State/Province
California
ZIP/Postal Code
92831
Country
United States
Facility Name
Duke University Eye Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16751032
Citation
Cotter SA; Pediatric Eye Disease Investigator Group; Edwards AR, Wallace DK, Beck RW, Arnold RW, Astle WF, Barnhardt CN, Birch EE, Donahue SP, Everett DF, Felius J, Holmes JM, Kraker RT, Melia M, Repka MX, Sala NA, Silbert DI, Weise KK. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology. 2006 Jun;113(6):895-903. doi: 10.1016/j.ophtha.2006.01.068.
Results Reference
result
PubMed Identifier
16751033
Citation
Wallace DK; Pediatric Eye Disease Investigator Group; Edwards AR, Cotter SA, Beck RW, Arnold RW, Astle WF, Barnhardt CN, Birch EE, Donahue SP, Everett DF, Felius J, Holmes JM, Kraker RT, Melia M, Repka MX, Sala NA, Silbert DI, Weise KK. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology. 2006 Jun;113(6):904-12. doi: 10.1016/j.ophtha.2006.01.069.
Results Reference
result
PubMed Identifier
22108357
Citation
Wallace DK, Lazar EL, Melia M, Birch EE, Holmes JM, Hopkins KB, Kraker RT, Kulp MT, Pang Y, Repka MX, Tamkins SM, Weise KK; Pediatric Eye Disease Investigator Group. Stereoacuity in children with anisometropic amblyopia. J AAPOS. 2011 Oct;15(5):455-61. doi: 10.1016/j.jaapos.2011.06.007.
Results Reference
derived
PubMed Identifier
20451898
Citation
Repka M, Simons K, Kraker R; Pediatric Eye Disease Investigator Group. Laterality of amblyopia. Am J Ophthalmol. 2010 Aug;150(2):270-4. doi: 10.1016/j.ajo.2010.01.040. Epub 2010 May 8.
Results Reference
derived
Links:
URL
http://pedig.net
Description
Pediatric Eye Disease Investigator Group

Learn more about this trial

Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children

We'll reach out to this number within 24 hrs